<DOC>
	<DOCNO>NCT00654121</DOCNO>
	<brief_summary>Prophylactic administration metabolically active insulin prevent delay clinical onset diabetes high risk group nondiabetic sibling define positivity autoantibody IA-2 ( IA-2-A ) .</brief_summary>
	<brief_title>Prevention Clinical Onset Type 1 Diabetes High Risk First Degree Relatives</brief_title>
	<detailed_description>Hypotheses : Primary : Prophylactic administration metabolically active insulin prevent delay clinical onset diabetes high risk group nondiabetic sibling define positivity autoantibody IA-2 ( IA-2-A ) . Secondary : 1 ) Untreated sibling positivity IA-2-A develop clinical diabetes significantly faster untreated offspring marker positivity . 2 ) Plasma proinsulin level increase disproportionately clinical onset Type 1 diabetes sibling offspring . 3 ) Prophylactic administration metabolically active insulin reduces plasma proinsulin/C-peptide ratio non-diabetic antibody positive sibling offspring . 4 ) Prophylactic administration metabolically active insulin reduces presence and/or level diabetes-associated autoantibody direct islet cell component . Endpoints : Fasting glycemia ; fast stimulate plasma C-peptide proinsulin value ; islet cell autoantibody ; incidence hypoglycemia ; body weight gain .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Sibling/offspring Type 1 diabetic patient good general condition age 539 year fast plasma glucose &lt; 126 mg/dL AND OGTT nondiabetic 1997 ADA criterion ( 33 ) : 1 . Normal glycemia : fasting plasma glucose &lt; 110 mg/dL 2 hour plasma glucose &lt; 140 mg/dL 2 . Impaired Fasting Glucose ( IFG ) : fast plasma glucose 110125 mg/dL 2 hour plasma glucose &lt; 140 mg/dL 3 . Impaired Glucose Tolerance ( IGT ) : fast plasma glucose &lt; 110 mg/dL 2 hour plasma glucose 140199 mg/dL least positive IA2A absence protective DQ genotype : A4B2/X X/Y X/X X = A2B3.3 , A1B1.9 , A1B1.2 , A4B3.1 , A2B2 A4.23B3.1 Y = A1B1.1 , A1B2 , A1B1.AZH , A3B2 , A3B3.1 , A3B3.3 , A3B4 , A4B4 , A4.23B4 , A4B3.2 , A3B1.1 , A4B3.3 , A4B1.1 A4.23B2 ( 32 ) cooperative reliable subject ( age ≥ 14 yr ) / parent ( age &lt; 14 yr ) give informed consent signature ; patient/parents inform sufficient detail content procedure protocol , indicate potential risk insulin therapy ; early intervention metabolically active insulin treatment identify clinical trial . Both parent sign agree protocol procedure . diabetes 1997 ADA criterion ( 33 ) : fast plasma glucose ≥ 126 mg/dL , 2 hour plasma glucose ≥ 200 mg/dL donation blood study within one month prior screen pregnancy lactation woman use inadequate anticonception female patient childbearing potential use illicit drug overconsumption alcohol ( &gt; 3 beers/day ) history drug alcohol abuse legally incapacitate , significant emotional problem time study , history psychiatric disorder receive antidepressant medication last 6 month treatment immune modulate diabetogenic medication ( corticosteroid ) presently participate another clinical study do last 12 month history illness , opinion investigator , might confound result study pose additional risk patient</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>39 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>prevention</keyword>
</DOC>